These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 16002336)

  • 21. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
    Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Akt in cancer therapy.
    LoPiccolo J; Granville CA; Gills JJ; Dennis PA
    Anticancer Drugs; 2007 Sep; 18(8):861-74. PubMed ID: 17667591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
    Mungamuri SK; Yang X; Thor AD; Somasundaram K
    Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions.
    Kaper F; Dornhoefer N; Giaccia AJ
    Cancer Res; 2006 Feb; 66(3):1561-9. PubMed ID: 16452213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting mammalian target of rapamycin (mTOR) for health and diseases.
    Tsang CK; Qi H; Liu LF; Zheng XF
    Drug Discov Today; 2007 Feb; 12(3-4):112-24. PubMed ID: 17275731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
    Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The biology behind mTOR inhibition in sarcoma.
    Wan X; Helman LJ
    Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway.
    Han B; Tong J; Zhu MJ; Ma C; Du M
    Mol Reprod Dev; 2008 May; 75(5):810-7. PubMed ID: 18033679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
    Janus A; Robak T; Smolewski P
    Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional consequences of mTOR inhibition.
    Sudarsanam S; Johnson DE
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [mTOR, the mammalian target of rapamycin].
    Julien LA; Roux PP
    Med Sci (Paris); 2010 Dec; 26(12):1056-60. PubMed ID: 21187044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Can defective TGF-Beta signaling be an Achilles heel in human cancer?].
    Foster DA; Gadir N
    Ai Zheng; 2008 Aug; 27(8):882-4. PubMed ID: 18710627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia].
    Dos Santos C; Récher C; Demur C; Payrastre B
    Bull Cancer; 2006 May; 93(5):445-7. PubMed ID: 16777621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the mTOR pathway using deforolimus in cancer therapy.
    Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
    Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Targeting of the AKT-mTOR pathway in head and neck and lung cancer].
    Vignot S; Haberer S; Besse B
    Bull Cancer; 2009; 96 Suppl 1():S57-63. PubMed ID: 19433374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The rationale for mTOR inhibition in epithelial ovarian cancer.
    Trinh XB; van Dam PA; Dirix LY; Vermeulen PB; Tjalma WA
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1885-91. PubMed ID: 19888868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to rapamycin through regulating phosphorylation of Akt in esophageal squamous cell carcinoma.
    Lu Z; Wang J; Zheng Y; Yang S; Liu M; Chen X; Wang C; Hou G
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26725440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.